Aquestive Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 12.05 million compared to USD 11.13 million a year ago. Net loss was USD 12.83 million compared to net income of USD 8.07 million a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.15 USD | +1.29% | -3.06% | +56.93% |
05-10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
05-08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.93% | 283M | |
+34.30% | 693B | |
+29.39% | 584B | |
-2.82% | 372B | |
+20.55% | 332B | |
+6.72% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.02% | 168B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024